Clinical Trial Update: Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing switching from Atripla to Eviplera versus continuing Atripla, examining changes in plasma lipid profiles in HIV-1–infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• Eviplera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate)

Snippet

Sponsor: Hospital Universitari Vall d'Hebron Research Institute | Conditions: HIV-1 | Phase 4 | Status: COMPLETED